Unum Therapeutics, which is developing antibody-coupled T-cell receptor immunotherapies for cancers, raised $69 million by offering 5.77 million shares at $12, the low end of the range of $12 to $14. At pricing, it commands a fully diluted market value of $380 million.
Backed by Atlas Venture, F-Prime Capital and Sanofi, Unum's insiders had indicated on up to $37.5 million of the deal (54%), with collaboration partner Seattle Genetics buying $5 million in a concurrent private placement.
Unum Therapeutics plans to list on the Nasdaq under the symbol UMRX. Morgan Stanley and Cowen & Company acted as lead managers on the deal.
